Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07179900 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

StatusRecruiting
PhasePhase 2
Started2025-03-01
View on ClinicalTrials.gov ↗

Amendment history

2026-07-31
Study Status, Contacts/Locations v2
Recruitment opened
Start dateestimated 2025-12→confirmed 2025-03-01
Study sites0→1
2025-12-04
Study Identification, Study Status, Eligibility, IPDSharing v1
Primary completion date2027-10→2027-12
Start date2025-10→2025-12
Eligibility criteria-742 characters
[...] ee to continue antiviral treatment during the study period; ⑧ No severe cardiovascular or cerebrovascular diseases; ⑨ Important organ functions should meet the following requirements: absolute neutrophil count (ANC) ≥ 1.0×10^9/L; platelet count ≥ 50×10^9/L; hemoglobin ≥ 9g/dL; serum creatinine (SCR) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance rate ≥ 50 ml/min (Cockcroft Gault formula); to [...] Women of childbearing age should agree to use contraceptive [...] asures during the study period and 6 months after the study; ⑪ Voluntarily sign the written informed consent form and comm [...] an [...]
2025-09-11
Original filing
This project is a prospective, open-label, randomized controlled clinical study. It plans to enroll 60 patients with unresectable HCC and no distant metastasis, randomly assigned to the experimental group and the control group, with 30 cases in each group. The experimental group was treated with radiotherapy combined with immunotherapy and Bevacizumab, while the control group was treated with immunotherapy and Bevacizumab. The efficacy of the patients and the conversion rate to surgery were evaluated.
Trial Details
NCT Number NCT07179900
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions Hepatocellular Carcinoma
Enrollment 60 participants
Start Date 2025-03-01
Primary Completion 2027-12 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-03